Chemical and nuclear properties of Rutherfordium (Element 104)

The chemical-properties of rutherfordium (Rf) and its group 4 homologs were studied by sorption on glass support surfaces coated with cobalt(II)ferrocyanide and by solvent extraction with tributylphosphate (TBP) and triisooctylamine (TIOA). The surface studies showed that the hydrolysis trend in the group 4 elements and the pseudogroup 4 element, lb, decreases in the order Rf>Zr{approx}Hf>Th. This trend was attributed to relativistic effects which predicted that Rf would be more prone to having a coordination number of 6 than 8 in most aqueous solutions due to a destabilization of the 6d{sub 5/2} shell and a stabilization of the 7p{sub l/2} shell. This hydrolysis trend was confirmed in the TBP/HBr solvent extraction studies which showed that the extraction trend decreased in the order Zr>Hf>Rf?Ti for HBr, showing that Rf and Ti did not extract as well because they hydrolyzed more easily than Zr and Hf. The TIOA/HF solvent extraction studies showed that the extraction trend for the group 4 elements decreased in the order Ti>Zr{approx}Hf>Rf, in inverse order from the trend of ionic radii Rf>Zr{approx}Hf>Ti. An attempt was made to produce {sup 263}Rf (a) via the {sup 248}Cm({sup 22}Ne, {alpha}3n) reaction employing thenoyltrifluoroacetone (TTA) solvent extraction chemistry and (b) via the {sup 249}Bk({sup 18}O,4n) reaction employing the Automated Rapid Chemistry Apparatus (ARCA). In the TTA studies, 16 fissions were observed but were all attributed to {sup 256}Fm. No alpha events were observed in the Rf chemical fraction. A 0.2 nb upper limit production cross section for the {sup 248}Cm({sup 22}Ne, {alpha}3n){sup 263}Rf reaction was calculated assuming the 500-sec half-life reported previously by Czerwinski et al. [CZE92A]

Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits

Gaucher disease is caused by defective acid β-glucosidase (GCase) function. Saposin C is a lysosomal protein needed for optimal GCase activity. To test the in vivo effects of saposin C on GCase, saposin C deficient mice (C−/−) were backcrossed to point mutated GCase (V394L/V394L) mice. The resultant mice (4L;C*) began to exhibit CNS abnormalities ∼30 days: first as hindlimb paresis, then progressive tremor and ataxia. Death occurred ∼48 days due to neurological deficits. Axonal degeneration was evident in brain stem, spinal cord and white matter of cerebellum accompanied by increasing infiltration of the brain stem, cortex and thalamus by CD68 positive microglial cells and activation of astrocytes. Electron microscopy showed inclusion bodies in neuronal processes and degenerating cells. Accumulation of p62 and Lamp2 were prominent in the brain suggesting the impairment of autophagosome/lysosome function. This phenotype was different from either V394L/V394L or C−/− alone. Relative to V394L/V394L mice, 4L;C* mice had diminished GCase protein and activity. Marked increases (20- to 30-fold) of glucosylsphingosine (GS) and moderate elevation (1.5- to 3-fold) of glucosylceramide (GC) were in 4L;C* brains. Visceral tissues had increases of GS and GC, but no storage cells were found. Neuronal cells in thick hippocampal slices from 4L;C* mice had significantly attenuated long-term potentiation, presumably resulting from substrate accumulation. The 4L;C* mouse mimics the CNS phenotype and biochemistry of some type 3 (neuronopathic) variants of Gaucher disease and is a unique model suitable for testing pharmacological chaperone and substrate reduction therapies, and investigating the mechanisms of neuronopathic Gaucher disease

Comparative Therapeutic Effects of Velaglucerase Alfa and Imiglucerase in a Gaucher Disease Mouse Model

Gaucher disease type 1 is caused by the defective activity of the lysosomal enzyme, acid β-glucosidase (GCase). Regular infusions of purified recombinant GCase are the standard of care for reversing hematologic, hepatic, splenic, and bony manifestations. Here, similar in vitro enzymatic properties, and in vivo pharmacokinetics and pharmacodynamics (PK/PD) and therapeutic efficacy of GCase were found with two human GCases, recombinant GCase (CHO cell, imiglucerase, Imig) and gene-activated GCase (human fibrosarcoma cells, velaglucerase alfa, Vela), in a Gaucher mouse, D409V/null. About 80+% of either enzyme localized to the liver interstitial cells and <5% was recovered in spleens and lungs after bolus i.v. injections. Glucosylceramide (GC) levels and storage cell numbers were reduced in a dose (5, 15 or 60 U/kg/wk) dependent manner in livers (60–95%) and in spleens (∼10–30%). Compared to Vela, Imig (60 U/kg/wk) had lesser effects at reducing hepatic GC (p = 0.0199) by 4 wks; this difference disappeared by 8 wks when nearly WT levels were achieved by Imig. Anti-GCase IgG was detected in GCase treated mice at 60 U/kg/wk, and IgE mediated acute hypersensitivity and death occurred after several injections of 60 U/kg/wk (21% with Vela and 34% with Imig). The responses of GC levels and storage cell numbers in Vela- and Imig-treated Gaucher mice at various doses provide a backdrop for clinical applications and decisions